UK - Braveheart leads £900,000 follow-on investment for Biopta

Biopta was formed as a spin-out from Glasgow Caledonian University in 2002. The company operates as a niche Contract Research Organisation (CRO), providing non-clinical services to the pharmaceutical, biotechnology and research industries, and has also developed a novel testing instrument under the brand name of Perf-Exion.

This transaction represents Biopta's third institutional funding round, following an initial investment in November 2004 and a follow-on round in June 2006, both of which were also backed by Braveheart. The new capital will be used to continue the expansion of the company's drug development services

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• UK / Ireland